JAC Advance Access originally published online on January 16, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 311-317
© 2004 The British Society for Antimicrobial Chemotherapy
Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis
1 Sumitomo Pharmaceuticals Research Division, 1–98, Kasugadenaka 3-chome, Konohana-ku, Osaka 554–0022; 2 Division of Respiratory Disease, Department of Medicine, Kawasaki Medical School, 577, Matsushima, Kurashiki 701–0192, Japan
Received 17 July 2003; returned 13 September 2003; revised 19 October 2003; accepted 5 November 2003
Objectives: The efficacy of intravenous injections of a liposomal formulation of amphotericin B (AmBisome) and amphotericin B deoxycholate (Fungizone) was evaluated in immunocompetent and temporarily leucopenic mouse models of disseminated aspergillosis using seven isolates of Aspergillus.
Methods: Mice were infected with the organisms via tail veins. At 4 h after infection, antifungals were administered intravenously. For 30 days the number of mice surviving was recorded.
Results: AmBisome at 1 mg/kg or higher significantly prolonged the survival time of mice infected with five out of seven isolates of Aspergillus compared with the control group. There was no difference in in vivo activity between AmBisome and Fungizone at 1 mg/kg in six isolates of Aspergillus. At the maximum tolerated dose of antifungals, however, AmBisome (10 mg/kg) showed greater efficacy than Fungizone (1 mg/kg).
Conclusions: These results suggest that the overall protective activity of AmBisome against disseminated aspergillosis is superior to that of Fungizone.
Keywords: liposomal amphotericin B, amphotericin B deoxycholate, Aspergillus, tolerability
* Corresponding author. Tel: +81-6-6466-5271; Fax: +81-6-6466-5491; E-mail: ktakemot{at}sumitomopharm.co.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Wang, L. Kong, J. Wang, X. He, X. Li, and Y. Xiao Polymyxin E sulfate-loaded liposome for intravenous use: preparation, lyophilization, and toxicity assessment in vivo. PDA J. Pharm. Sci. Technol., March 1, 2009; 63(2): 159 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Brock, G. Jouvion, S. Droin-Bergere, O. Dussurget, M.-A. Nicola, and O. Ibrahim-Granet Bioluminescent Aspergillus fumigatus, a New Tool for Drug Efficiency Testing and In Vivo Monitoring of Invasive Aspergillosis Appl. Envir. Microbiol., November 15, 2008; 74(22): 7023 - 7035. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takemoto, Y. Yamamoto, Y. Ueda, Y. Sumita, K. Yoshida, and Y. Niki Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis J. Antimicrob. Chemother., April 1, 2006; 57(4): 724 - 731. [Abstract] [Full Text] [PDF]
|
|